Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

HMR grants Matrix rights to anticancer agent about to enter phase II

Sep. 25, 1998

Oxigene updates Neu-Sensamide development status

Sep. 25, 1998

Biomira and Biovector collaborate on development of idiotypic B-cell lymphoma vaccine

Sep. 24, 1998

New paclitaxel formulation enters clinical trials

Sep. 24, 1998

Another series of DC-107 derivatives from Kyowa Hakko particularly useful as antitumor agents

Sep. 24, 1998

Hydroxamic acids as cancer cell differentiation inducers under study at Mitsui Chemicals

Sep. 24, 1998

Expanded approval requested for chemoprotective agent

Sep. 24, 1998

First chemically synthesized ribozyme heading for human studies for cancer

Sep. 23, 1998

New MMP inhibitors in early development at Ono

Sep. 23, 1998

Kyowa Hakko studies DC-107 derivatives as antitumor/antibacterial agents

Sep. 23, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...